Autonomous Blood Drawing Optimization and Performance Testing (ADOPT)

Vitestro

Status: Enrolling

Conditions: Phlebotomy; Venipuncture

Treatments: Device: Venipuncture Device (VD)

Study type: Interventional

Funder types: Industry

Identifiers

NCT05878483

NL80965.000.22

Details and patient eligibility

About

The purpose of this pre-market clinical study is to evaluate the performance (efficacy) and safety of an autonomous blood drawing device (Venipuncture Device).

The study consists of several phases (A, B1, B2, B3, C1, C2, C3, 0).

Phase B1 is a confirmatory, Pivotal Clinical Study, required for regulatory approval, in which non-inferiority should be demonstrated in comparison to manual blood drawing.

Phases A, B2, B3, C1, C2, C3 are all exploratory studies, in which the technology and usability is further improved and tested. Phase 0 is an exploratory study for non-invasive technology testing (for example for improvement of ultrasound detection).

The study locations are outpatient blood drawing departments, in which patients are included as subjects. Additionally, in Phase A and C1, a small number of volunteers can be included in a non-hospital site (Vitestro Site).

Enrollment: 44,658 estimated patients

Sex: All

Ages: 16+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Age ≥16 years.

Exclusion criteria

• Unable to follow instructions, due to mental disability and/or incapacity
• Unable to use device correctly due to physical impairment or disability (for example a patient with severe contractures or deformities)
• No venipuncture possible in cubital fossa of both arms (for example: after amputation of both arms)
• No venipuncture possible in cubital fossa due to contra-indications in both arms (for example: tattoos in both arms)
• Incapacitated persons
• Pregnant or breast-feeding

The following contra-indications / exclusion criteria are respected per arm:

• Arteriovenous fistula or vascular graft
• Paretic or paralyzed arm (e.g. after stroke or trauma)
• Infected skin in cubital fossa (for example: erysipelas or cellulitis)
• Mastectomy side, axillary lymph node excised
• Healed skin burns in cubital fossa
• Edema in cubital fossa
• Extensive scarring in cubital fossa
• Hematoma in cubital fossa
• Tattoos in cubital fossa

In case the test subject has a suitable contralateral arm, the subject can be included in this study. In Study Phase B2 or B3, venipunctures are performed in both arms. Patients who have a contra-indication in one arm are excluded from the Phase B2 and Phase B3 study.

Trial design

Primary purpose: Other

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

44,658 participants in 1 patient group

Autonomous blood drawing

Experimental group

Description:

Hospital Sites (outpatients visiting blood drawing department): In study Phase A, B1, B2, C1, a subject visiting the outpatient blood drawing department will receive one automated blood draw with the Venipuncture Device. This blood draw is additional to the manual blood draw. In study Phase C2 and Phase C3 the automated blood draw replaces the manual blood draw. In both Phases, the subject might therefore receive two automated blood draws, in case a redraw is required. In study Phase B3, the automated blood draw also replaces the manual blood draw. The subject will receive two automated blood draws. Vitestro Site (volunteers): In study Phase A, C1 volunteers visit Vitestro Site. Participants receive one to two automated blood draws.

Treatment:

Device: Venipuncture Device (VD)